

# Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients

## *An experience from Western Saudi Arabia*

Abdulkader M. Albasri, MBBCH, PhD, Mohammed A. Elkablawy, MSc, PhD, Akbar S. Hussainy, FCPS, PDFPath [Canada], Hala M. Yousif, MSc, MD, Ahmed S. Alhujaily, MBBCH, KSUFP.

### ABSTRACT

**الأهداف:** دراسة أثر زيادة مستوى بروتين (COX-2) على تطور سرطان القولون والمستقيم.

**الطريقة:** أجريت هذه الدراسة الإسترجاعية في قسم علم الأمراض بمستشفى الملك فهد بالمدينة المنورة خلال الفترة من يناير 2006م إلى ديسمبر 2017م، حيث تم صبغ 324 حالة سرطان و 40 حالة ورم حميد و 20 حالة من نسيج أمعاء طبيعي.

**النتائج:** وقد اتضح زيادة مستوى البروتين في 40% من الأنسجة الطبيعية السليمة وكذلك زيادة في مستوى البروتين في 65% من الأورام الحميدة. أما في حالات السرطان، فقد اتضح زيادة البروتين في 84.6% من الحالات. لم تلاحظ أي علاقة إحصائية بين زيادة مستوى البروتين COX-2 وبين أعمار المرضى وجنسياتهم ومكان الورم وكذلك حجم الورم. ومع ذلك فقد لوحظ أن هناك علاقة إحصائية بين زيادة مستوى البروتين وبين نوع الورم وتمايزه وانتشاره في العقد اللمفاوية والأوعية الدموية اللمفاوية وباقي أجزاء الجسم وكذلك بينه وبين مستويات تطور الورم المتقدمة وزيادة نسبة بروتين ال Ki 67. وقد أثبتت الدراسة أيضا أن بروتين COX-2 يعتبر من مؤشرات الإنذارات المستقلة الهامة والوحيدة التي تؤثر على حياة المرضى المصابين بسرطان القولون والمستقيم.

**الخاتمة:** وقد انتهت الدراسة إلى أن زيادة مستوى بروتين COX-2 في مراحل سرطان القولون والمستقيم الأولية والعلاقة بينه وبين مستويات تطور الورم المتقدمة وزيادة نسبة بروتين ال Ki67 مما يثبت بوضوح أثر زيادة مستوى بروتين COX-2 على تطور سرطان القولون والمستقيم.

**Objectives:** To evaluate cyclooxygenase-2 (COX-2) over-expression in colorectal cancer (CRC) and its role in carcinogenesis and prognosis.

**Methods:** It was a retrospective study. Archival samples were obtained from Pathology Department at King Fahad Hospital, Madinah, Saudi Arabia, over 11 years

period (January 2006 to December 2017). Samples were analyzed using immunohistochemistry for COX-2 and Ki67 over-expression in 324 CRC patients, 40 cases of colorectal adenomas and 20 cases of normal colonic mucosa.

**Results:** Cyclooxygenase-2 over-expression was observed in 40% of normal colonic mucosa, 65% of colorectal adenoma and 84.6% of CRC cases. There were no significant correlations between COX-2 over-expression and age, gender, tumor site, or tumor size. However, COX-2 over-expression revealed highly significant correlations with tumor differentiation, lymph node metastasis, lympho-vascular invasion, distant metastasis, advanced stages, and high Ki67 expression. Univariate Kaplan-Meier survival analysis showed that patients with high COX-2 expression had significantly shorter periods of survival. Multivariate analysis by means of the COX-2 regression model revealed that high COX-2 over-expression, AJCC, and Ki67 expression were the only significant independent prognostic indicators.

**Conclusion:** Cyclooxygenase-2 over-expression increases during normal-adenoma-carcinoma sequence, moreover COX-2 over-expression is associated with advanced tumor stage and Ki67 over-expression. These findings suggest a significant role of COX-2 in the carcinogenesis and prognosis of CRC in our study population.

*Saudi Med J* 2018; Vol. 39 (8): 773-780  
doi:10.15537/smj.2018.8.22837

From the Department of Pathology, Taibah University, Madinah, Kingdom of Saudi Arabia.

Received 29th April 2018. Accepted 13th July 2018.

Address correspondence and reprint request to: Dr. Abdulkader M. Albasri, Head of Pathology Department, c: abdbasri@hotmail.com

Colorectal cancer (CRC) is one of the most common cancers in the world today, being second most common in the female population and third in the males. More than half [55%] cases of CRC occur in the developed countries. The incidence of CRC is very low in Asian and African countries. Although there is a great geographical variation in the incidence across the globe; the geographical pattern is similar within the 2 genders.<sup>1</sup> The Kingdom of Saudi Arabia (KSA) belongs to low CRC incidence region; CRC is still the second common, after, according to the latest Saudi cancer registry.<sup>2</sup> Analysis of KSA CRC suggests a potentially disturbing rise in CRC in near future, but no formal surveillance programs have yet been established in the Kingdom.<sup>3</sup> In the latest hospital and pathology-based study from the region of Al-Madinah, most of the CRC patients were diagnosed in an advanced stage.<sup>4</sup> There is a well-established link between chronic inflammation and carcinogenesis. Several inflammatory mediators and cytokines appear to be involved in this pathogenesis, one of them being the family of cyclooxygenases. These are the enzymes involved in prostaglandin biosynthesis; the isoform cyclooxygenase-2 (COX-2) is found to be up regulated in inflammations and cancers.<sup>5</sup> The over-expression of COX-2 is associated with poor prognosis in CRC patients. The growth and progress of CRC has been reported to accompany COX-2 gene over-expression. High levels of COX-2 over-expression were more frequent in early colorectal lesions. Furthermore, COX-2 over-expression in the normal tissue adjacent to the tumor may also be involved in the tumorigenesis of CRC. Thus, these interpretations seem to be useful in defining the importance of COX-2 over-expression in the tumorigenesis of CRC.<sup>6</sup> Cyclooxygenase-2 over-expression appears to provide useful prognostic information for CRC, while predicting the patients who are at a higher risk for recurrence.<sup>7</sup> However, the prognostic value of COX-2 over-expression on CRC patient survival has yet to be established using large-scale prospective trials.<sup>8,9</sup>

The aim of this study is to immunohistochemically examine the COX-2 biomarker in CRC patients and to correlate the COX-2 findings with clinicopathological prognostic parameters and the proliferative marker Ki67. This study is significant because no similar study has been performed in our region in KSA, and such a

study would be helpful in establishing any predictive or prognostic role of COX-2 in managing CRC patients within the KSA population.

**Methods.** Generic search engines namely Google and MSN Bing search engines were utilized; as well as specific medical search engines Pubmed/Medline, Science Direct, Scopus and Google scholar were used for search of preceding scientific literature research. The present study was a retrospective study involving the archival histopathology material and record; and did not involve patients' personal information or any implication upon the management; thus, was according to the principles of Helsinki Declaration. Hence no ethical approval was mandatory in the present study.

This retrospective study included 324 consecutive cases of CRC diagnosed at the Pathology Department, King Fahad Hospital, Madinah, Saudi Arabia, over a period of 11 years (January 2006 to December 2017). Clinicopathological data were obtained from patients' medical records and included gender, age, tumor type, size, site, grade, lymphovascular invasion, lymph nodes status, American Joint Committee on Cancer (AJCC) stages of CRC, and Ki67 immunostaining results.

In the present study, 40 colorectal adenoma cases and 20 normal colonic mucosa cases were used as controls. The inclusion criterion was histologically confirmed invasive CRC cases. Whereas the exclusion criteria were in-situ lesions, recurrences, biopsies, benign lesions, and metastatic lesions. All total colectomies, hemicolectomies, and excision specimens were included in the analysis.

**Immunohistochemical procedures.** Cores of sample tissues were extracted from archival paraffin blocks of CRC and utilized in the construction of tissue miniarray (TmA), as previously described.<sup>10</sup> Four-micrometer-thick tissue sections were cut from the TmA blocks, mounted on charged poly-l-lysine-coated slides, and followed by immunohistochemistry (IHC) using the Avidin Biotin detection system according to the manufacturer's instructions. The antibody used was a human anti-COX-2 monoclonal antibody (diluted in 1:50 blocking solution; Clone 4A4, Ventana Inc., Tucson, AZ, United States). Sections were double-stained with another antibody (anti-Ki67; diluted 1:100, in blocking solution; Ventana Inc., Tucson, AZ, United States). Immunohistochemistry was carried out by an automatic immune-stainer (Ventana Bench Mark XT; Ventana Inc., Tucson, AZ, United States). Sample of normal prostatic tissue was used as a positive control for COX-2. Negative controls were accomplished by replacing the primary antibody with serum.

**Disclosure.** Authors have no conflict of interests, and the work was not supported or funded by any drug company.

**Interpretation of immunohistochemical staining.**

Distinct yellow to brown staining of cellular cytoplasm was considered positive for COX-2. The authors (AMA and MAE) reviewed the immunostaining independently and the average score was taken. The level of COX-2 over-expression was calculated by combining an estimate of the percentage of immuno-reactive cells (quantity score) with an estimate of the staining intensity (staining intensity score). No staining was scored as 0, 1-10% of cells with positive staining were scored as 1, 10-50% as 2, 50-70% as 3, and 70-100% as 4. Staining intensity was rated on a scale of 0 to 3 as follows: 0 = negative (no staining); 1 = weak, 2 = moderate, and 3 = strong. The final expression score was expressed as follows: '-' for scores 0, '+' for scores 1-3, '++' for scores 4-6 and '+++' for scores >6. For statistical analysis, we combined the cases that scored as '-' and '+' (low score) and compared them to the cases that scored as '++' and '+++' (high score).

**Statistical analysis.** Data analysis was performed by utilizing the Statistical Package for Social Sciences (SPSS) Version 22.0 for Windows (IBM Corp, Armonk, NY, USA). Correlation analysis between the 2 data sets was used to assess the inter observer reproducibility. Chi-squared and Fisher's exact tests were performed to determine the association between the COX-2 expression and patient clinicopathological parameters. The cumulative patient survival was assessed by the Kaplan-Meier method. Finally, the long-rank test was used for comparison of the survival curves. The COX-2 proportional hazard linear regression model was performed by forward stepwise procedure, to look for the independent factors independently associated with survival. A p value of  $\leq 0.05$  was considered significant for all statistical analyses.

**Results. Clinicopathological characteristics of the cases.** A total of 324 patients were included in the study. There were 196 cases (60.5%) males and 128 cases (39.5%) females giving a male to female ratio of 1.5:1. The age of the studied cases ranged from 22 to 96 years with a mean age 56.9 years. Left-sided tumors were more common than the right-sided and seen in 63.5% of cases. Tumor size was  $\geq 4$  cm in 84% of the studied cases. The most common histologic type was adenocarcinoma, seen in 279 cases (86.1%). Most of tumors were moderately differentiated (80.2%). The majority of patients were diagnosed in stage II (44.7%) and stage III (31.5%) according to the AJCC. Approximately 44.8% of cases had positive lymph node metastasis and lymphovascular invasion, where distant metastasis were seen in 30.3% of cases.

**Table 1** - The clinicopathological features of 324 colorectal cancer (CRC) cases.

Variables	n	(%)
<b>Age (years)</b>		
<40	177	(54.6)
$\geq 40$	147	(45.4)
<b>Gender</b>		
Female	128	(39.5)
Male	196	(60.5)
<b>Tumor site</b>		
Colon	168	(51.9)
Rectum	156	(48.1)
<b>Tumor size</b>		
<4cm	52	(16.0)
$\geq 4$ cm	272	(84.0)
<b>Tumor type</b>		
Adenocarcinoma	279	(86.1)
Mucinous adenocarcinoma	45	(13.9)
<b>Tumor differentiation</b>		
Well	49	(15.1)
Moderate	260	(80.2)
Poor	15	(4.7)
<b>Lymph node</b>		
Negative	179	(55.2)
Positive	145	(44.8)
<b>Lymphovascular invasion</b>		
Negative	179	(55.2)
Positive	145	(44.8)
<b>Distant metastasis</b>		
Negative	281	(86.7)
Positive	43	(13.3)
<b>AJCC</b>		
I	34	(10.5)
II	145	(44.7)
III	102	(31.5)
IV	43	(13.3)

AJCC - American Joint Committee on Cancer

Table 1 summarizes the clinicopathological characteristics of 324 CRC cases.

**Cyclooxygenase-2 over expression profiles.** In the normal colonic mucosa, COX-2 over-expression was observed in 40% cases (8 of 20 cases); whereas in colorectal adenoma samples, COX-2 was over-expressed in 65% cases (26 of 40 cases). In CRC, COX-2 expression was high in most cases namely, 274 cases (84.6%), and low in only 50 cases (15.4%) (Figure 1). Similarly, a higher COX-2 over expression was observed in high-grade villous adenomas as compared to low-grade tubular adenomas ( $p=0.081$ ).

**Correlation of COX-2 expression with the clinicopathological features.** Cyclooxygenase-2 over-expression did not show any significant correlation when compared with age, gender, tumor site and tumor

**Table 2** - Correlation of COX-2 expression with the clinicopathological variables and Ki67 immunophenotyping of colorectal cancer (CRC) cases.

Variables	Low COX-2	High COX-2	P-value
<i>Age (years)</i>			0.287
<40	25	152	
≥40	25	122	
<i>Gender</i>			0.11
Female	12	116	
Male	38	158	
<i>Tumor site</i>			0.183
Colon	26	142	
Rectum	24	132	
<i>Tumor size</i>			0.217
<4cm	28	145	
≥4cm	22	129	
<i>Tumor type</i>			0.026
Adenocarcinoma	38	241	
Mucinous adenocarcinoma	12	33	
<i>Tumor differentiation</i>			<0.001
Well	19	30	
Moderate	31	229	
Poor	0	15	
<i>Lymph node</i>			0.001
Negative	38	141	
Positive	12	33	
<i>Lymphovascular invasion</i>			0.001
Negative	38	141	
Positive	12	33	
<i>Distant metastasis</i>			<0.001
Negative	50	231	
Positive	0	43	
<i>AJCC stage</i>			<0.001
I	19	15	
II	19	126	
III	12	90	
IV	0	43	
<i>Ki67</i>			<0.001
Low	23	39	
High	27	235	

COX-2 - cyclooxygenase-2, AJCC - American Joint Committee on Cancer

size. On the contrary, COX-2 over-expression exhibited a significant correlation with tumor type ( $p=0.026$ ); whereas highly significant correlations were seen with tumor differentiation ( $p<0.001$ ), positive lymph node metastasis ( $p<0.001$ ), lympho-vascular invasion ( $p<0.001$ ), distant metastasis ( $p<0.001$ ), advanced AJCC stages ( $p<0.001$ ), and high Ki67 expression ( $p<0.001$ ). **Figure 2** depicts the association between increased COX-2 immunoexpression and increased Ki67 immunoexpression. The summary of correlation of COX-2 over-expression with clinicopathological variables depicted in **Table 2**.


**Table 3** - Test statistics for equality of survival distribution for prognostic factors examined in 324 colorectal carcinomas. A univariate approach to cancer-specific mortality.

Factor	Univariate $\chi^2$ for the log-rank	Degree of freedom	P-value
<i>Clinicopathological factors</i>			
AJCC stage	772.81	3	<0.001
Lymph node stage	400.28	1	<0.001
Metastasis stage	507.58	1	<0.001
Lymphovascular invasion	400.28	1	<0.001
Histological tumor grade	170.27	2	<0.001
Tumor size	2.141	1	0.133
Tumor site	2.360	1	0.212
Tumor type	1.153	1	0.283
Age	0.308	1	0.579
Gender	0.064	1	0.800
Immunostaining			
Cox2 immunostaining	71.67	1	<0.001
Ki67 immunostaining	23.91	1	<0.001


COX-2 - cyclooxygenase-2, AJCC - American Joint Committee on Cancer

**Univariate and multivariate long-term survival analysis.** All the significant features associated with survival ( $p<0.05$ ) for the 324 CRC patients in the study are depicted in **Table 3**. **Figure 3** exhibit significant survival curves for COX-2 immunoprofile. Significantly short survival was observed in patients with high COX-2 over-expression than the patients with low COX-2 over-expression ( $p<0.001$ ). High COX-2 expression ( $p<0.001$ ), AJCC ( $p<0.001$ ) and Ki67 expression ( $p<0.014$ ) were the only significant independent prognostic indicators, as calculated by multivariate analysis of COX regression model.


**Discussion.** Cyclooxygenase is a rate-limiting enzyme in the prostaglandin metabolism and has 2 isoforms COX-1 and COX-2. The extensively studied isoform COX-2 is the enzyme, which is up regulated in response to cytokines, growth factors and several tumor-promoting factors. Its pathophysiological role has been well recognized in inflammations, healing and repair as well as in carcinogenesis. The carcinogenetic effects of COX-2 have been studied in cancers of various organs such as breast,<sup>11</sup> lung,<sup>12</sup> esophagus,<sup>13</sup> head and neck,<sup>14</sup> bladder,<sup>15</sup> and liver.<sup>16</sup> Cyclooxygenase-2 has also been found to be over-expressed in CRC.<sup>7,9,17</sup> This role of COX-2 in the human malignancies, including CRC was discovered by recent epidemiological studies, which reported an approximately 50% decrease in the relative risk of CRC in individuals using non-steroidal anti-inflammatory drugs; suggesting that these drugs might have protective and therapeutic effects.<sup>18</sup>



**Figure 1** - Different patterns of immunohistochemical COX-2 expression in A) normal colon (weak cytoplasmic positivity), B) colonic adenoma (mild to moderate cytoplasmic positivity), C) colorectal carcinoma (marked granular cytoplasmic expression), and D) lymph node metastasis CRC (marked granular cytoplasmic expression). Arrows indicate COX-2 cytoplasmic expression.



**Figure 2** - Immunohistochemical characterization of colorectal cancer specimens showing high levels of Ki67 expression confirming the association between increased (+++) COX-2 immunopositivity and increased (+++) Ki67 immunopositivity. Arrows indicate COX-2 cytoplasmic expression and Ki67 nuclear expression.



**Figure 3** -Shows Kaplan-meier curves for significant overall survival functions for Cox2 expression in CRC.

In this study, we found that COX-2 expression was up regulated in the sequence from normal to adenoma to adenocarcinoma, in concordance with the findings of a number of previous studies suggesting the pathogenic role of COX-2 in CRC.<sup>19</sup> However, the over expression of COX-2 in the adjacent normal mucosa had been an important point of discussion in the past. Some studies reported a higher expression of COX-2 in adjacent

normal mucosa as compared to that of CRC mucosa;<sup>20</sup> whereas in contrast, some studies have observed absence of COX-2 expression in the normal mucosa near the CRC.<sup>21</sup> Recently Lin et al<sup>6</sup> from Taiwan, have studied the COX-2 expression in the CRC and normal mucosa, through IHC and western blotting methodologies. They observed that most of their patients had low levels of COX-2 expression in CRC tissue and high levels of COX-2 expression in adjacent normal mucosa. These observations confirm our findings of COX-2 expression in normal mucosa; although we found higher tumor to normal mucosa expression ratio of COX-2. Lin et al<sup>6</sup> observed a high ratio of tumor to normal tissue COX-2 expression only in correlation with high recurrence rates and poor prognosis; we found the similar correlation with higher tumor stage. Thus, we agree with their conclusion that COX-2 expression in normal tissue adjacent to tumors may be important for CRC carcinogenesis.

The role of COX-2 expression and its inhibitors have also been studied in depth for its association with the colorectal adenoma, in an attempt to prove its carcinogenetic importance. Recently, a review on COX-2 over-expression and chemoprevention of CRC, report four randomized studies, which have shown that daily aspirin use reduces the occurrence of colorectal adenomatous polyps among individuals with a history of prior colorectal adenomas or cancer.<sup>22</sup> In the same year, Wasilewicz et al<sup>23</sup> demonstrated that high COX-2 expression is associated with distinctive risk factors in the process of malignant transformation of colonic polyps.<sup>23</sup> In contrast, a group of scientists from Brazil, in a study using TmA and IHC on positivity and intensity of COX-2 did not find any significant differences between the adenomas and the non-neoplastic colorectal mucosa.<sup>24</sup> Our findings in the present study are however in concordance with most of the recent works regarding its over-expression and its significance as precancerous marker in the colorectal adenoma-carcinoma sequence. We observed a trend of COX-2 over-expression in high-grade villous adenomas as compared to low-grade tubular adenomas. Our findings are in concordance with a recent study reporting statistically significant differences in high COX-2 expressions in high-grade dysplastic adenomas versus adenomas without dysplasia. They also report similar significant differences between low-grade dysplastic adenomas versus adenomas without dysplasia.<sup>23</sup> In 2010, a large study by Benamouzig et al, reported that over-expression of COX-2 was frequent and predominated in large and high-grade dysplastic adenomas.<sup>25</sup> Yet another study on colorectal polypi observed that COX-2 over-expression is infrequent in

hyperplastic polyp, sessile serrated polyp/adenomas (SSA) and mixed polypi, as compared to non-serrated and serrated adenoma. Cyclooxygenase-2 over-expression becomes more frequent as tumors progress to higher-grades.<sup>26</sup>

In contrast to normal mucosa and adenoma samples, we found very high COX-2 expression in CRC samples, which correlated with higher stage tumors in our patient cohort. Kazem et al,<sup>7</sup> from Egypt have recently reported statistically significant relationships between pathological grade and COX-2 positivity scores. Dimberg et al<sup>27</sup> from Sweden also report COX-2 over-expression in CRC, however they observed this over-expression to be significantly higher in rectal carcinomas as compared to other locations of colon, probably due to differences in gene regulatory factors affecting COX-2 expression. Our observations are also in concordance with that of similar study on the carcinogenetic role of COX-2.<sup>28</sup> No correlation was observed between COX-2 over-expression versus gender, age, tumor size, tumor and tumor location; similarly, Chinese scientists in their COX-2 study in CRC also could not find any correlation between the over-expression of COX-2 with gender, age, or tumor location.<sup>29</sup> Likewise, Egyptian group of scientists, found no significant correlation between COX-2 over-expression and clinicopathological parameters, such as age, gender, tumor location.<sup>7</sup> From within the KSA, similar were the observations by a group of researchers namely, they did not find any significant correlations between COX-2 over-expression and gender, age, grade or tumor location.<sup>8</sup> However, in our study, a significant correlation of COX-2 over-expression with lymph node metastasis, distant metastasis and advanced AJCC stage, as observed by the Saudi group of scientists.<sup>8</sup> Moreover, a highly significant association was observed between over expression of COX-2 and high expression of the proliferative marker ki67, which is in concordance with a number of previous studies.<sup>30-32</sup> Thus, our findings concerning the COX-2 over-expression and clinicopathological parameters are in keeping with that of similar studies from the world and nation.

Previous studies have reported a direct relationship between COX-2 over-expression and patient survival in CRC. Our results in univariate and multivariate survival analysis support the theory that COX-2 over-expression is associated with a worse patient survival as compared to COX-2 negativity. Similar results have been reported and supported the prognostic role of COX-2 in CRC patients.<sup>8,30</sup>

In conclusion, we studied COX-2 in our CRC patients through TmA and IHC techniques, and found increasing percentage of COX-2 over-expression from normal to adenoma to carcinoma sequence. Similarly, a trend of high COX-2 over-expression was observed in high-grade villous adenomas as compared to low-grade tubular adenomas. Moreover, we observed significant correlations for advanced AJCC stage, as well as for increased expression of Ki67. All these findings suggest a significant role of COX-2 expression in carcinogenesis and progression of CRC. Thus, we confirm that COX-2 and Ki67 over-expression can be used as a reliable indicator for prognosis of CRC patients.

**Acknowledgment.** *The authors would like to thank the Deanship of Scientific Research, Taibah University, Almadinah Almonawwarah, Saudi Arabia, for their encouragement and support. The authors would also like to thank Dr. Alla Khadri (Pathology Department, Taibah University, Saudi Arabia) for revising the grammar and language. And also thank to Mr. Mohamed Abdelsammad, Mr. Rayid Alharbi, and Mrs. Faten Bokhary (laboratory technician, Taibah University, Saudi Arabia) for technical advice. Furthermore, we would like to thank Scribendi, the Editing and Proofreading Services for English Documents (<https://www.scribendi.com/>) for the English language editing of the manuscript.*

## References

- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Globocan 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. [2015 November 2015]. Lyon (FR): International Agency for Research on Cancer; 2013.
- International Association of Cancer Registries. Saudi Cancer Incidence Report 2014. Saudi Cancer Registry. Riyadh (KSA): King Faisal Specialist Hospital & Research Center Council of Health Services; 2017.
- Ibrahim EM, Zeeneldin AA, El-Khodary TR, Al-Gahmi AM, Bin Sadiq BM. Past, Present and Future of Colorectal Cancer in the Kingdom of Saudi Arabia. *Saudi J Gastroenterol* 2008; 14: 178-182.
- Albasri A, Yosef H, Hussainy AS, Sultan SA, Alhujaily AS. Histopathological features of colorectal cancer in Al-Madinah region of Saudi Arabia: 8 years experience. *Asian Pac J Cancer Prev* 2014; 15: 3133-3137.
- Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. Role of Cyclooxygenase-2 in cell proliferation and cell death in human malignancies. *Int J Cell Biol* 2010; 2010: 215158.
- Lin PC, Lin YJ, Lee CT, Liu HS, Lee JC. Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients. *Oncol Lett* 2013; 6: 733-739.
- Kazem A, El Sayed K, El Kerm Y. Prognostic significance of COX-2 and  $\beta$ -catenin in colorectal carcinoma. *Alexandria Journal of Medicine* 2014; 50: 211-220.
- Al-Maghrabi J, Buhmeida A, Emam E, Syrjänen K, Sibiany A, Al-Qahtani M, et al. Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. *World J Gastroenterol* 2012; 18: 1793-9.
- Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. *PLoS One* 2013; 8: e58891.
- Elkablawy MA, Albasri AM. High quality tissue miniarray technique using a conventional TV/radio telescopic antenna. *Asian Pac J Cancer Prev* 2015; 16: 1129-1133.
- Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. *Clin Breast Cancer* 2004; 4: 428-433.
- Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, et al. Has COX-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. *Br J Cancer* 2006; 95: 139-145.
- Li L, Zhao J, Wu Z, Wang G, Chen G. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. *Aliment Pharmacol Ther* 2009; 30: 589-596.
- Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. *Head Neck* 2002; 24: 792-799.
- Hammam OA, Aziz AA, Roshdy MS, Abdil Hadi A. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal associated bladder cancer. *Medscape J Med* 2008; 10: 60.
- Bayomi EA, Barakat AB, El-Bassuoni MA, Talaat RM, El-Deftar MM, Abdel Wahab SA, et al. Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma. *J Cancer Res Ther* 2015; 11: 786-792.
- Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. *J Clin Oncol* 2005; 23: 2840-2855.
- Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, et al. Chemo prevention of colorectal cancer: systematic review and economic evaluation. *Health Technol Assess* 2010; 14: 1-206.
- Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. *N Engl J Med* 2006; 355: 885-895.
- Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. *Br J Cancer* 2009; 101: 106-115.
- Sano H, Kawahito Y, Wilder RL, Hashimoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. *Cancer Res* 1995; 55: 3785-3789.
- Chan AT. COX-2 expression in adenoma: an imperfect marker for chemoprevention. *Gut* 2010; 59: 568-569.
- Wasilewicz MP, Kołodziej B, Bojułko T, Kaczmarczyk M, Sulzyc-Bielicka V, Bielicki D. Expression of cyclooxygenase-2 in colonic polyps. *Pol Arch Med Wewn* 2010; 120: 313-320.
- Nogueira RB, Pires AR, Soares TM, Rodrigues SR, Campos MA, Toloí GC et al. Immunoeexpression of the COX-2, p53, and caspase-3 proteins in colorectal adenoma and non-neoplastic mucosa. *Einstein* 2013; 11: 456-461.
- Benamouz R, Uzzan B, Martin A. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemo prevention. *Gut* 2010; 59: 622-629.

26. Kawasaki T, Nosho K, Ohnishi M. Cyclooxygenase-2 over-expression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. *BMC Cancer* 2008; 8: 33.
27. Dimberg J, Samuelsson A, Hugander A. Differential expression of cyclooxygenase 2 in human colorectal cancer. *Gut* 1999; 45: 730-732.
28. Dixon DA, Blanco FF, Bruno A. Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia. *Recent Results In Cancer Research* 2013; 191: 7-37.
29. Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. *World J Gastroenterol* 2015; 21: 6206-6214.
30. Jafarian AH, Kermani AT, Esmaili J. The role of COX-2 and Ki-67 over-expression in the prediction of pathologic response of rectal cancer to neoadjuvant chemoradiation therapy. *Indian J Cancer* 2016; 53: 548-551.
31. Güler SA, Uğurlu MU, Kaya H, Şen S, Nazlı Y, M, Güllüoğlu BM. Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients. *Güllüoğlu Ulus Cerrahi Derg* 2016; 32: 81-88.
32. Joo Y, Chung I, Park Y, Koh YS, Lee JH, Park CH, et al. Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer. *J Korean Med Sci* 2006; 21: 871-876.